Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib After Chemotherapy in Newly Diagnosed AML
NCT04659616Phase 1Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2021
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pemigatinib in acute myeloid leukemia (AML), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Incidence of dose limiting toxicities up to 42 days. Started Jan 2021; status: recruiting.
02
Drugs
pemigatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04659616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659616.